GLP-1 and muscle loss —
what the medication cannot do.

A few months ago somebody sat across from me who had lost fifteen kilos in half a year. Numbers better, trousers two sizes smaller, doctor pleased. Except the stairs at the office were harder than before, his grip on a suitcase was gone, and in training he was managing loads he had used as a warm-up two years earlier.

That is not an argument against the medication. It is an argument for looking more closely at what a weight loss consists of. The scale shows a number. It does not show whether you gave up fat or muscle.

One thing up front, because it belongs to the stance: I am not a doctor. What follows is an assessment from twenty years of training practice, not a treatment recommendation. Prescription, dosage and suitability are decided by medical professionals, and rightly so. What I can judge is the part that comes afterwards: what happens to a body that loses a lot of weight in a short time, and what can be done about it.

What these medications do in the body

GLP-1 is not a synthetic invention. It is a hormone your own gut releases after eating, glucagon-like peptide 1. It performs several jobs at once, and that combined action is what makes it interesting as a drug.

It stimulates insulin release, but only when blood glucose is elevated. That is why these substances alone rarely cause hypoglycaemia. At the same time it suppresses glucagon, insulin's counterpart. It slows gastric emptying, so food stays in the stomach longer. And it acts on the brain regions that regulate hunger and satiety.

That last point is the decisive one for the weight effect. People on these medications eat less, because appetite drops and fullness arrives sooner. The drug does not burn fat. It changes how much you eat.

Injection and pill, briefly

Two mechanisms are in use as injections. Semaglutide mimics GLP-1, given weekly. Tirzepatide acts dually, binding additionally to the GIP receptor, a second gut-hormone system. In the licensing trials this produces stronger weight effects.

The oral form contains the same active substance in tablet form, but needs an absorption enhancer and a strict intake routine, because peptides are normally broken down in the stomach. Fasted, with little water, followed by a waiting period. I name active substances here deliberately and brand names not. Choosing a specific product belongs in a medical practice, not in a blog article.

What is proven: weight, blood sugar, heart

Fairness belongs here, even from somebody who comes from the training side. For a drug of this kind, the evidence on weight is unusually strong.

In the STEP 1 trial, participants on 2.4 mg semaglutide weekly lost a mean 14.9 per cent of body weight over 68 weeks, against 2.4 per cent on placebo. For tirzepatide, the SURMOUNT-1 figures ranged from 16.0 to 22.5 per cent depending on dose, against 2.4 per cent on placebo. Those are magnitudes rarely reached with lifestyle measures alone from that starting point.

More interesting than the weight are the hard endpoints. In the SELECT trial with 17,604 participants, all with overweight and pre-existing cardiovascular disease but without diabetes, major cardiovascular events occurred in 6.5 per cent on semaglutide against 8.0 per cent on placebo. That corresponds to a hazard ratio of 0.80 over close to 40 months.

There are also signals of kidney benefit in people with type 2 diabetes and kidney disease. That group sits outside the scope here, so it stays a footnote and without figures.

What you must not read into SELECT: that this benefit applies to somebody ten kilos above their target weight and otherwise healthy. The trial was run in people at substantial risk. For the healthy forty-year-old with a slight belly, that evidence does not exist.

The point missing from the marketing

Now to what matters from a longevity perspective and appears in hardly any brochure. Under rapid weight loss the body does not only give up fat.

The review Muscle matters in The Lancet Diabetes & Endocrinology summarises the available data as follows: the decline in fat-free mass accounts for 25 to 39 per cent of total weight lost, measured over 36 to 72 weeks. The authors rate that as considerably higher than with non-pharmacological caloric restriction or normal ageing.

Fat-free mass is not the same as muscle. It also contains water, connective tissue and bone mineral. The point still stands: a relevant share of what the scale no longer shows is not fat.

Why this weighs more at sixty than at thirty

Muscle is not a cosmetic organ. It is the body's largest consumer of glucose, it accounts for a substantial part of resting metabolism, and it determines whether you can still get up off the floor unaided at eighty. Skeletal muscle mass declines from around the age of fifty anyway, year by year. Losing additional muscle through rapid weight loss during that phase simply brings the curve forward.

Bone density belongs here too. Under substantial weight loss the mechanical load on the skeleton drops, and bone responds to missing load by breaking down. For people over fifty that is not cosmetic, it is a fall risk with consequences.

And the counter-argument that belongs in the picture

This is where it gets genuinely uncomfortable, including for my own position. In a widely noted viewpoint in JAMA, Conte, Hall and Klein ask whether muscle mass loss under medically induced weight loss is clinically relevant at all. Their argument: people carrying a lot of body fat have often also built above-average muscle in order to move that mass around. A decline could therefore be partly an adaptation to the new, lower weight. The authors note that studies are still missing on whether preserving muscle justifies the cost and possible side effects of additional therapy.

That position is not unreasonable, and it comes from people who understand body composition. I do not follow it to its conclusion, but it belongs in the article. My counter-argument is a practical one: strength training and adequate protein are cheap, low in side effects and worth doing regardless of the medication. Anyone already doing the right thing never has to settle the question of clinical relevance.

Why managed strength training makes the difference

The medication lowers appetite. It does not tell the body where the missing energy should come from. The body makes that decision itself, and it makes it by usefulness. Muscle that is not being asked for is, from its point of view, expensive ballast.

This is exactly where training acts. A sufficient strength stimulus is the signal that this muscle is needed. Without the signal, it gets broken down. It is no coincidence that the same logic applies to bed rest, spaceflight and long injury layoffs.

The difference between "a bit of movement" and an effective stimulus is routinely underestimated. Walking is good for many things. It is not a signal to preserve muscle. Nor is a handful of machine sets with no progression over months.

Strength is also a skill, not only a property. Anyone who owns the technique can create more stimulus with less volume, and that counts double when recovery is already limited. How to progress load sensibly is covered under progression, and what specifically changes with strength training after forty is in the overview on that.

I am sceptical of anything sold as a shortcut. I was sceptical of protein bars and vibration plates too, so consider me biased. It does not change the mechanism though: appetite regulation and body composition are two different jobs. A medication can do the first one. Not the second.

What happens after stopping

The extension of the STEP 1 trial looked at what happens when the medication is withdrawn. One year after stopping, participants in the semaglutide group had regained 11.6 percentage points of the weight they had lost. Of the original loss, a net 5.6 per cent remained. Part of the cardiometabolic improvement also drifted back towards baseline.

That carries an unpleasant consequence which is rarely discussed. If muscle was lost on the way down and mostly fat comes back on the way up, body composition shifts in the wrong direction with every cycle. The same weight as before, with less muscle inside it.

Which is exactly why the question of strength training is not an add-on to the therapy. It decides what condition the body is in once the medication stops.

Who it suits, and who it does not

I do not assess individual cases, that is not my role. But a few patterns can be named without attaching a diagnosis to anybody.

It can make sense where there is substantial obesity, where comorbidities are present, and where serious attempts through nutrition and exercise have not been enough over a longer period. That is also where the evidence behind the licensing sits.

I would be more reserved with people of normal weight chasing the last five kilos, with athletes in weight categories, with people who have a history of eating disorders, and with anyone obtaining the drug without medical supervision through questionable channels. That last point is not a moral argument but a safety one.

On one point I am unambiguous: anyone who treats the medication as a replacement for lifestyle rather than a tool beside it will be standing in the same place in two years, just with less muscle.

The conclusion from a coach's perspective is unspectacular. These medications are an effective tool for a clearly defined group, and they are not a miracle cure. They solve one part of the problem, namely energy intake. Everything that decides how capable you are in ten years still runs through training, nutrition and recovery. Where this topic sits in the wider picture is placed under longevity. And if you are looking for a training framework that works alongside such a therapy, you will find one in the Blueprint Digital.